P647 2-year incidence of new immune-mediated inflammatory diseases in patients with inflammatory bowel disease. The AQUILES study

Marín-Jiménez, Ignacio; García, Vicente; Javier, Perez-Gisbert; Pérez-Calle, J.L.; Lujàn, M.; Tabernero, Susana; Andreu, M.; Vicuña, Rosario García de; Juliá, Berta; Cea‐Calvo, Luis; Vanaclocha, F.

doi:10.1016/s1873-9946(14)60767-4

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, EIMs were described in 16 publications, with their presence ranging from 7.0% to 28.7% for overall IBD (Table 4 ). A higher prevalence of EIM in patients with CD compared to patients with UC was observed in five out of seven publications with available data [ 19 , 30 , 33 – 35 ]. The most common EIM was osteoarticular manifestations, reported in over 10% of patients for both CD and UC.…”

Section: Resultsmentioning

confidence: 99%

“…Between 13.5% [ 35 ] and 26.6% [ 36 ] of adult patients with IBD in the studies had at least one other immune-mediated inflammatory disease (IMID)…”

Section: Resultsmentioning

confidence: 99%

“…Psychiatric comorbidities were frequently reported, with depression described in up to 20% and anxiety in up to 11% of patients with CD and UC [ 19 , 30 , 33 – 35 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Introduction This study describes the epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), in Spain. Methods A systematic review was performed of observational studies reporting the epidemiological, clinical, patient-reported and economic burden of IBD in the Spanish population, from 2011 to 2021. Original articles and conference abstracts published in English or Spanish were eligible. Results A total of 45 publications were included in the review. The incidence of IBD in adults ranged from 9.6 to 44.3 per 100,000 inhabitants (4.6 to 18.5 for CD and 3.4 to 26.5 for UC). The incidence increased between 1.5- and twofold from 2000 to 2016 (regionally). Up to 6.0% (CD) and 3.0% (UC) IBD-associated mortality was reported. Disease onset predominantly occurs between 30 and 40 years (more delayed for UC than CD). Most frequently reported gastrointestinal manifestations are rectal bleeding in UC and weight loss in CD. Extraintestinal manifestations (EIM) have been described in up to 47.4% of patients with CD and 48.1% of patients with UC. Psychiatric comorbidities were frequently reported in both CD and UC (depression up to 20% and anxiety up to 11%). Reduced health-related quality of life (HRQoL) compared to the general population was reported. Significant symptomatology was associated with high levels of anxiety, depression, stress and lower HRQoL. Main healthcare resources reported were emergency department visits (24.0%), hospitalization (14.7%), surgery (up to 11%) and use of biologics (up to 60%), especially in CD. Direct and indirect annual costs per patient with UC were €1754.1 and €399.3, respectively. Conclusion Patients with CD and UC present a high disease burden which negatively impacts their HRQoL, leading to elevated use of resources. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02473-6.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Between 13.5% [ 35 ] and 26.6% [ 36 ] of adult patients with IBD in the studies had at least one other immune-mediated inflammatory disease (IMID)…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A focus of our research includes identifying the immune cells that play a role in the pathogenesis of IBD. At present, therapy for IBD mostly involves inhibiting intestinal inflammation ( 11 ). Immunotherapy that can regulate the intestinal barrier also provides a new idea for treating IBD.…”

Section: Introductionmentioning

confidence: 99%

The role of intestinal immune cells and matrix metalloproteinases in inflammatory bowel disease

et al. 2023

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) has become globally intractable. MMPs play a key role in many inflammatory diseases. However, little is known about the role of MMPs in IBD. In this study, IBD expression profiles were screened from public Gene Expression Omnibus datasets. Functional enrichment analysis revealed that IBD-related specific functions were associated with immune pathways. Five MMPS-related disease markers, namely MMP-9, CD160, PTGDS, SLC26A8, and TLR5, were selected by machine learning and the correlation between each marker and immune cells was evaluated. We then induced colitis in C57 mice using sodium dextran sulfate and validated model construction through HE staining of the mouse colon. WB and immunofluorescence experiments confirmed that the expression levels of MMP-9, PTGDS, SLC26A8, and CD160 in colitis were significantly increased, whereas that of TLR5 were decreased. Flow cytometry analysis revealed that MMPs regulate intestinal inflammation and immunity mainly through CD8 in colitis. Our findings reveal that MMPs play a crucial role in the pathogenesis of IBD and are related to the infiltration of immune cells, suggesting that MMPs may promote the development of IBD by activating immune infiltration and the immune response. This study provides insights for further studies on the occurrence and development of IBD.

show abstract

“…Up to one-third of patients with Crohn’s disease (CD) may present extraintestinal articular manifestations, and less frequently dermatological and ocular manifestations. 1 Granulomatous cheilitis, characterized by persistent inflammation of the lips and a granulomatous histology, is sometimes associated with CD and is a therapeutic challenge. 2–4 When conventional treatments fail, treatment with a tumour necrosis factor antagonist (anti-TNF) has been successful in isolated cases.…”

Section: Introductionmentioning

confidence: 99%

Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review

Taxonera

Alba

Colmenares

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Granulomatous cheilitis, characterized by persistent inflammation of the lips and a granulomatous histology, is sometimes associated with Crohn’s disease and is a therapeutic challenge. Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments. The clinical case reported the effectiveness of ustekinumab, a monoclonal antibody against interleukins 12/23, to induce the remission of severe and recurrent granulomatous cheilitis in a patient with Crohn’s disease.

show abstract

P647 2-year incidence of new immune-mediated inflammatory diseases in patients with inflammatory bowel disease. The AQUILES study

Cited by 4 publications

References 0 publications

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

The role of intestinal immune cells and matrix metalloproteinases in inflammatory bowel disease

Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review

Contact Info

Product

Resources

About